Would you consider using CDK 4/6 inhibitors in a patient with end stage renal disease (ESRD) along with an aromatase inhibitor?
If so, please describe your experience and dosing.
Answer from: Medical Oncologist at Academic Institution
The short answer is yes. Here is why...All three CDK4/6 inhibitors are extensively metabolized by the liver and excreted in the feces. Based on the known PK profiles of all 3 commercially available CDK4/6 inhibitors, there should not be a dose reduction necessary in patients with CKD (although these...
Sign in or Register to read more